All In Biotech

Drug Trial Radar · NCT07710885

Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer

A Phase 3, Randomized-Controlled, Open-Label, Multi-Regional, International Study of Futibatinib (TAS-120) and Zimberelimab (AB122) in Combination With Gemcitabine Plus Cisplatin Versus Durvalumab or Pembrolizumab in Combination With Gemcitabine Plus Cisplatin for Patients With First-Line Advanced Biliary Tract Cancers

Last checked: Nov 19, 2026Latest source record: Jul 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 784 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

784

Planned (sponsor's estimate)

Start

Jun 24, 2026

Primary completion

Apr 30, 2030

Study completion Dec 31, 2031

Sponsor

Lead sponsor
Taiho Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
Collaborators
Taiho Oncology, Inc.
First posted
Jul 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To compare overall survival (OS) of patients in Futibatinib and Zimberelimab in Combination with Gemcitabine plus Cisplatin versus Durvalumab or Pembrolizumab in Combination with Gemcitabine plus Cisplatin for patients with first-line advanced biliary tract cancer

Conditions

  • Biliary Tract Cancer

Interventions

  • FutibatinibDrug

    Futibatinib 20 mg will be administered orally once daily.

  • ZimberelimabDrug

    Zimberelimab 360 mg will be administered on Day 1 of each 3-week cycle (Q3W) by intravenous infusion.

  • DurvalumabDrug

    Durvalumab 1500 mg will be administered on Day 1 of Q3W by intravenous infusion.

  • PembrolizumabDrug

    Pembrolizumab 200 mg will be administered on Day 1 of Q3W by intravenous infusion.

  • GemcitabineDrug

    Gemcitabine 1000 mg/m2 will be administered Days 1 and 8 of Q3W by intravenous infusion.

  • CisplatinDrug

    Cisplatin 25 mg/m2 will be administered Days 1 and 8 of Q3W by intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: Up to approximately 45 months

Locations

21 sites in 4 countries. Site status is shown where the registry gives one.

  • Research Site

    Brisbane, Australia · Not yet recruiting

  • Research Site

    Melbourne, Australia · Not yet recruiting

  • Research Site

    Perth, Australia · Not yet recruiting

  • Research Site

    Sydney, Australia · Not yet recruiting

  • Research Site

    Aichi, Japan · Not yet recruiting

  • National Hospital Organization Kyushu Cancer Center

    Fukuoka, Japan · Recruiting

  • Research Site

    Fukuoka, Japan · Not yet recruiting

  • Research Site

    Hokkaido, Japan · Not yet recruiting

  • Kanagawa Cancer Center

    Kanagawa, Japan · Not yet recruiting

  • Research Site

    Miyagi, Japan · Not yet recruiting

  • Research Site

    Osaka, Japan · Not yet recruiting

  • Research Site

    Tokyo, Japan · Not yet recruiting

  • The Cancer Institute Hospital

    Tokyo, Japan · Recruiting

  • Toyama University Hopspital

    Toyama, Japan · Recruiting

  • Wakayama Medical University Hospital

    Wakayama, Japan · Recruiting

  • Research Site

    Busan, South Korea · Not yet recruiting

  • Research Site

    Hwasun, South Korea · Not yet recruiting

  • Research Site

    Seongnam, South Korea · Not yet recruiting

  • Research Site

    Seoul, South Korea · Not yet recruiting

  • Research Site

    Bangkok, Thailand · Not yet recruiting

  • Research Site

    Chiang Mai, Thailand · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.